Completed
PHASE3
INTERVENTIONAL
NCT03001817
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and \<2000 mg/dL and normal renal function.
Interventions
Name:
K-877
Type:
DRUG
Description:
Name:
Fenofibrate
Type:
DRUG
Description:
Name:
Placebo (for K-877)
Type:
DRUG
Description:
Name:
Placebo (for Fenofibrate)
Type:
DRUG
Description:
Primary Outcomes
Measure:
Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12
TimeFrame:
12 Weeks
Description:
Trial Information
NCT ID
NCT03001817
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Kowa Research Institute, Inc.
Last Updated
December 15, 2025